Invest1 publisher3 min readPublished
A Bristol Myers Phase 1 will price Orum's degrader platform in February 2027
Orum halted an earlier antibody-degrader conjugate in April last year after a death and unexplained liver toxicity. The candidate Bristol Myers is testing in leukemia sits on the same platform, and a second in-house candidate uses the same degrader.
The Investor · Invest desk
What happened
- Daol Investment & Securities says the outcome of the Bristol Myers-run Phase 1 of Orum's lead antibody-degrader conjugate, due to complete its primary evaluation next year, will determine the platform's value and its prospects for further licensing deals.
- The clinical trial registry puts primary completion of that Bristol Myers trial in February 2027, with the candidate, ORM-6151, being tested in patients with acute myeloid leukemia and myelodysplastic syndrome.
- Orum ended development of an earlier candidate, the HER2-targeting ORM-5029, in April last year after serious adverse events and a death occurred in a Phase 1 trial in 2024.
- ORM-1153, developed in-house, won approval of a US investigational new drug application last month, and Orum says it aims to start a Phase 1 trial of it this year.
- Orum licensed a candidate to Bristol Myers in 2023 and signed a multi-target licensing and option agreement with Vertex in 2024 worth up to $945 million.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- exposure Orum owns the platform story but not the experiment that settles it: Bristol Myers runs the trial, so the timing and the content of what shareholders eventually see are the partner's call.
- constraint Because the two candidates nearest to patients use the same GSPT1 degrader, a human tolerability problem in leukemia would be harder for Orum to contain to a single molecule.
- decision Orum is committing money to a solid tumor candidate selection and preclinical package before the human safety question on its lead conjugate has an answer.
- contradiction Daol frames the February readout as decisive for platform value while also crediting PROTAb with a payload-agnostic saving in development time that would matter whatever ORM-6151 does.
Twenty-two months separate the halt of ORM-5029 from the registry's primary completion date for the Bristol Myers study [6][18][19]. It was suggested at the time that the linker had released the degrader prematurely in the bloodstream, though nobody confirmed that the linker caused the liver toxicity [7], and Orum treated the failure as specific to that candidate, improving the antibody and linker structures in its follow-on pipeline [8].
The degrader repeats across the pipeline. ORM-6151 pairs a CD33-targeting antibody with a GSPT1 degrader [3], and ORM-1153 pairs a CD123-targeting antibody with a GSPT1 degrader [9], so two of the programs closest to patients carry the same payload [20]. What Orum has published on the second one is a 93% fall in leukemia cell burden in a mouse model and no serious toxicity on repeat dosing in monkeys [10].
Primary completion is a registry milestone, not a publication date [5]. BMS runs the trial, and the study has more than one arm: monotherapy alongside a triplet combination with azacitidine and venetoclax [4]. In a first-in-human study in acute myeloid leukemia and myelodysplastic syndrome, the first thing outside shareholders are likely to learn is whether BMS keeps dosing.
The only disclosed platform-level figure is the Vertex ceiling, and "up to" on a multi-target option agreement is a payment schedule contingent on the partner exercising [11]. Daol Investment & Securities did not disclose terms for the 2023 BMS license, and its note is silent on whether ORM-6151 uses the improved antibody and linker structures [23].
Daol said using PROTAb removes the need to design a new linker from scratch every time, shortening development timelines by six to nine months [15]. Orum's own solid tumor schedule is a check on that: selecting ORM-1023 in the fourth quarter of this year and releasing preclinical data in the first half of next year is at most about nine months of work, from October to June [13][22]. The screen behind that program covered more than 250 cell lines across more than 20 cancer types [12], an average of roughly twelve lines per type [21].
In my view the February result will move the platform's value more than any deal Orum signs before it, because the question a partner cannot answer from mouse and monkey data is whether antibody-delivered GSPT1 degradation is tolerated in people [10][20]. Two other paths are live. The trial completes, BMS says little, and the platform stays priced on the Vertex options and on ORM-1153's own Phase 1 for another year [11][9]. Or the leukemia data are clean, and the harder question becomes whether a CD33 conjugate adds anything on top of azacitidine and venetoclax [4]. A liver signal in the BMS trial would break the thesis, put the linker back at the centre, and leave the candidate-specific explanation covering neither ORM-1153 nor ORM-1023 [7][8][9][13].
What to watch
- Whether BMS releases ORM-6151 safety and response data around the February 2027 primary completion date or holds it back for a later conference.
- Whether Orum begins dosing ORM-1153 before the end of this year, as it says it intends to.
- Whether the ORM-1023 candidate selection lands in the fourth quarter and names its degrader target in the preclinical package.